New nasal spray COVID booster enters human testing

NCT ID NCT07536308

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 7 times

Summary

This early-stage trial is testing a new COVID-19 booster vaccine called OCU500, which is given as a nasal spray or inhaled mist instead of a shot. The study involves 80 healthy adults aged 18-64 who have already been vaccinated against COVID-19. Researchers are checking if the vaccine is safe and whether it triggers a strong immune response in the nose and blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCU500 (a COVID-19 booster vaccine given as a nasal spray or inhaled mist)
What this could lead to: If it works, this could provide a more convenient and potentially more protective booster against COVID-19, especially against newer variants.
What could go wrong: This is a very early Phase 1 trial with only 80 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115-6110, United States
Saint Louis University Center for Vaccine Development
RECRUITING

St Louis, Missouri, 63104-1015, United States
The Hope Clinic of Emory University
RECRUITING

Decatur, Georgia, 30030-1705, United States
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
RECRUITING

Baltimore, Maryland, 21201-1509, United States

Contact Email: •••••@•••••
University of Texas Medical Branch
RECRUITING

Galveston, Texas, 77555-0435, United States
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit
WITHDRAWN

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.